NMDA antagonists as Parkinson’s disease therapy: disseminating the evidence (original) (raw)
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
Imtiaz Ahmed
Brain, 2011
View PDFchevron_right
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and parkinsonism
Frank Menniti, Michael Krams
Movement Disorders, 2008
View PDFchevron_right
Therapeutic potential of targeting glutamate receptors in Parkinson’s disease
Clare Kent
Journal of Neural Transmission, 2014
View PDFchevron_right
NMDA antagonists for treating the non-motor symptoms in Parkinson's disease
Itai Danovitch
Translational psychiatry, 2018
View PDFchevron_right
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease
Ralph Mazenko
Clinical neuropharmacology
View PDFchevron_right
A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease
Jordi Ramirez
Experimental Neurology, 2005
View PDFchevron_right
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Nicola Tambasco, Veronica Ghiglieri
The Lancet Neurology, 2010
View PDFchevron_right
Prevention of levodopa-induced dyskinesias by a selective NR1A/2BN-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin
Abdallah Tahar
Movement Disorders, 2006
View PDFchevron_right
Rebalance of Striatal NMDA/AMPA Receptor Ratio Underlies the Reduced Emergence of Dyskinesia During D2-Like Dopamine Agonist Treatment in Experimental Parkinson's Disease
V. Ghiglieri
The Journal of Neuroscience, 2012
View PDFchevron_right
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
Akash Roy
Postgraduate Medical Journal, 2007
View PDFchevron_right
Investigating group III metabotropic glutamate receptors as novel therapeutic targets in Parkinson's disease and Levodopa-induced dyskinesia
Clare Kent
2014
View PDFchevron_right
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment
Giorgio Bernardi
Brain, 2002
View PDFchevron_right
Molecular Mechanisms and Therapeutic Strategies for Levodopa-Induced Dyskinesia in Parkinson’s Disease: A Perspective Through Preclinical and Clinical Evidence
Awanish Mishra
Frontiers in Pharmacology, 2022
View PDFchevron_right
Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts
Aristide Merola
Annals of Neurology
View PDFchevron_right
Levodopa in the treatment of Parkinson's disease: an old drug still going strong
Angelo Antonini
2010
View PDFchevron_right
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease
Frank Menniti
Experimental Neurology, 2004
View PDFchevron_right
The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease
Olivier Rascol
Journal of Neurology, 2000
View PDFchevron_right
Glutamate release inhibition ineffective in Levodopa-induced motor complications
Murat Aksu
Movement Disorders, 2006
View PDFchevron_right
Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys
Laurent Grégoire
Neurobiology of Disease, 2004
View PDFchevron_right
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson?s disease
Christelle Baunez
Psychopharmacology, 2005
View PDFchevron_right
−NMDA R/+VDR pharmacological phenotype as a novel therapeutic target in relieving motor–cognitive impairments in Parkinsonism
Balogun Gbolahan
Drug and Chemical Toxicology, 2015
View PDFchevron_right
N-Methyl-D-Aspartate Antagonists in Levodopa Induced Dyskinesia: A Meta-Analysis
Behzad Elahi
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2012
View PDFchevron_right
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias
Jon Stoessl
Brain, 2004
View PDFchevron_right
AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study
Mark Stacy
Movement Disorders, 2013
View PDFchevron_right
Levodopa in the treatment of Parkinson's disease: Current controversies
ariadna galvan
Movement Disorders, 2004
View PDFchevron_right
Levodopa‐induced dyskinesias in Parkinson's disease: Is sensitization reversible?
Roberto Marconi
Annals of Neurology, 2000
View PDFchevron_right
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients
Francesco Errico
Scientific Reports
View PDFchevron_right
Current Pharmacotherapeutic Treatment Options in Parkinson’s Disease
Michael Rezak
Dm Disease-a-month, 2007
View PDFchevron_right